Efficacy of Dienogest on Pelvic Pain and Dyspareunia: Comprehensive Meta-Analysis and Systematic Review

Sutrisno Sutrisno, Wildan Aulia Firdaus
In: Asian Journal of Health Research · 2023 · vol. 2(1) , pp. 82–88 · doi:10.55561/ajhr.v2i1.73 · W4361273604
article OA: diamond CC0 ⤵ 4 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Dienogest significantly improved pelvic pain and dyspareunia compared to placebo in women with endometriosis, based on a meta-analysis of five studies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This paper is a PRISMA-guided systematic review and random-effects meta-analysis evaluating how dienogest affects pelvic pain and dyspareunia in women with endometriosis, comparing it with placebo or combined oral contraceptives (COC). Across five included studies (n=711), dienogest was associated with substantially improved pelvic pain and dyspareunia versus placebo, and COC showed substantially improved both dyspareunia and pelvic pain versus dienogest. A key limitation explicitly reflected in the methods is that the review included only five studies meeting eligibility criteria, which constrains the evidence base. This paper is centrally about endometriosis — it specifically meta-analyzes dienogest’s efficacy for endometriosis-related pelvic pain and dyspareunia.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction: Endometriosis is a severe disorder marked by endometrial tissue outside the uterus and linked to infertility, although typically manifesting as discomfort in the form of dysmenorrhea, dyspareunia, and pelvic pain. Dienogest is indicated as a first-line hormone treatment for endometriosis-related discomfort. The aim of this study is to analyze the efficacy of Dienogest on treating pelvic pain and dyspareunia compared to placebo or combined oral contraceptives (COC) in women with endometriosis. Methods: A systematic search is conducted in PubMed, ScienceDirect, and Google Scholar. The PRISMA 2020 rules were used to screen the articles that were obtained. For the review, studies that examined how using dienogest in improving endometriosis were exposed to were taken into consideration. In a meta-analysis utilizing a random-effects model, odds ratios with their 95% confidence intervals (CI) were provided. Results: Five studies that met the criteria for inclusion were determined to be pertinent to the association between using dienogest in improving endometriosis (n=711). The Dienogest group had substantially improve pelvic pain with a mean difference of 1.01 (95% CI 1.2, 0.82; p<0.00001) and dyspareunia with a mean difference of 0.58 (95% CI 1.09, 0.08; p=0.02) compared to placebo. Compared to combined oral contraceptives, COC had substantially improves dyspareunia with a mean difference of 0.99 (95% CI 0.62, 1.37; p<0.00001) and pelvic pain with a mean difference of 1.15 (95% CI 0.23, 0.83; p=0.01). Conclusion: Dienogest should be considered as an alternate treatment for endometriosis-related symptoms. In double-blind research, DNG efficacy was compared to placebo.
Full text 2,096 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Keywords

Dienogest , Combined Oral Contraceptive , Endometriosis , Pelvic Pain , DyspareuniaAbstract

Introduction

Endometriosis is a severe disorder marked by endometrial tissue outside the uterus and linked to infertility, although typically manifesting as discomfort in the form of dysmenorrhea, dyspareunia, and pelvic pain. Dienogest is indicated as a first-line hormone treatment for endometriosis-related discomfort. The aim of this study is to analyze the efficacy of Dienogest on treating pelvic pain and dyspareunia compared to placebo or combined oral contraceptives (COC) in women with endometriosis.

Methods

A systematic search is conducted in PubMed, ScienceDirect, and Google Scholar. The PRISMA 2020 rules were used to screen the articles that were obtained. For the review, studies that examined how using dienogest in improving endometriosis were exposed to were taken into consideration. In a meta-analysis utilizing a random-effects model, odds ratios with their 95% confidence intervals (CI) were provided.

Results

Five studies that met the criteria for inclusion were determined to be pertinent to the association between using dienogest in improving endometriosis (n=711). The Dienogest group had substantially improve pelvic pain with a mean difference of 1.01 (95% CI 1.2, 0.82; p<0.00001) and dyspareunia with a mean difference of 0.58 (95% CI 1.09, 0.08; p=0.02) compared to placebo. Compared to combined oral contraceptives, COC had substantially improves dyspareunia with a mean difference of 0.99 (95% CI 0.62, 1.37; p<0.00001) and pelvic pain with a mean difference of 1.15 (95% CI 0.23, 0.83; p=0.01).

Conclusion

Dienogest should be considered as an alternate treatment for endometriosis-related symptoms. In double-blind research, DNG efficacy was compared to placebo. Downloads Published Issue Section License Copyright (c) 2023 Sutrisno Sutrisno; Wildan Aulia Firdaus This work is licensed under a Creative Commons Attribution 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisdysmenorrheadyspareuniainfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Cited by (4)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK